MO — Claude Opus 4.8

I'll research MO (Altria Group) before writing the preview. Let me start by gathering recent earnings materials, filings, and news.Let me read the most recent earnings call (2026Q1) and the year-ago Q2 (2025Q2) materials, plus check recent news.Let me get the year-ago Q2 base numbers, the Q1 2026 release details, recent news, and stock performance.Let me grab the Q1 2026 release headline numbers and search for recent news on the CEO transition and any catalysts.Let me check the May 2026 8-K (likely CEO transition detail) and search for the new CEO name.I have what I need. Let me compute a few price/return stats to ground the market-setup section.# Altria Group (MO) — Q2 2026 Earnings Preview

Reports before market open, Thursday, July 30, 2026 (2026Q2 Earnings Call, 9:00 a.m. ET)

The one-line setup

Altria heads into Q2 as a "boring winner" that has stopped being boring: the stock is up ~26% over the past year and sits near multi-year highs (~$75), the cigarette-volume decline is unexpectedly moderating, and this will be the first quarter reported under a brand-new CEO and CFO. The bar has quietly risen, so the debate is less "can they hit the number" and more "is the good news already in the price?"

1. Management transition — the biggest change since last report

This is the first earnings call not run by long-time CEO Billy Gifford. Following the May 14, 2026 annual meeting: - Salvatore Mancuso (previously CFO) became CEO. - Heather A. Newman became EVP & CFO. - Gifford retired and stays on as a paid consultant through year-end 2026 to smooth the handoff.

Why it matters for the print: Mancuso is a known quantity to investors (he handled most of the financial Q&A on recent calls), so continuity risk is low. But listen for (a) any change in tone on capital allocation / smoke-free investment cadence, and (b) whether new leadership uses its first call to reset expectations or reaffirm the status quo. New CEOs sometimes "kitchen-sink" guidance; the setup here (stock near highs, strong H1) argues against it, but it's the key wildcard.

2. What the numbers should look like

Guidance context: Altria reaffirmed FY2026 adjusted diluted EPS of $5.56–$5.72 (+2.5% to +5.5%) off a $5.42 2025 base, and after a strong Q1 said 2026 growth should now be more balanced between the first and second half (previously more 2H-weighted).

Q1 2026 actuals (the momentum): adjusted EPS $1.32, +7.3%; net revenue +3.2% to $5.4B; revenue net of excise +5.3%.

Q2 2026 rough frame: the year-ago Q2 2025 base was adjusted EPS $1.44 (+8.3% then). Applying the FY growth algorithm, a Q2 in the ~$1.47–$1.51 zone would be consistent with "balanced" H1/H2 delivery. Given Q1 ran hot at +7.3%, anything materially below ~+3% YoY could read as decelerating momentum.

Segment expectations to check against Q1's trends: | Item | Q1 2026 trend | What to watch in Q2 | |---|---|---| | Smokeable adj OCI | +6.3%, margin 65.1% | Can pricing (~6%) + volume moderation sustain 6%+ growth? | | Cigarette shipments (adj.) | −4% (industry −5%) | Continued moderation vs. the −10.5% seen in Q2 2025 | | Oral adj OCI | +0.2% (flat), margin 67.4% (−1.8pp) | Helix investment drag vs. on! PLUS ramp | | ABI equity earnings | +9.6% to $160M | One-quarter-lag contribution |

3. The bull case that's building: cigarette volume moderation

The most important fundamental shift is that the cigarette industry volume decline is decelerating — Q1 industry volume was down ~5% (adjusted), the fourth consecutive quarter of sequential year-over-year moderation, versus roughly −8.5% a year earlier. Management attributes this to two forces: 1. Reduced cross-category movement to illicit flavored disposable vapes (helped by stepped-up enforcement — including a DEA-supported action in Northern Virginia — and state product directories). 2. Saturation of the e-vapor category, slowing the historical bleed from cigarettes.

If Q2 confirms a third straight quarter of ~4–5% (rather than reverting to high-single-digit declines), it validates the thesis that combustible cash flows are more durable than the market long assumed — the core driver of the stock's re-rating. This is the single most important line item in the release.

Counterpoint / risk: the low-end consumer is stretched. Discount segment share jumped +2.4 pts YoY in Q1 as trade-down accelerated, and Marlboro's total share slipped to 39.7% (−1.4 pts) even as it held/gained in the more profitable premium segment (59.5%). Higher gas prices late in Q1 and fading tax-refund tailwinds could pressure the price-sensitive smoker further. Watch mix: strong discount growth (Basic) is share-accretive but margin-dilutive relative to premium.

4. Smoke-free: the swing factor for the multiple

on! / nicotine pouches (oral): - The nicotine pouch category now exceeds 58% of total oral tobacco and is growing fast, but on! is losing category share — down to 13.4% of the pouch category (−4.2 pts YoY) even as absolute on! shipments grew ~18%. - on! PLUS (soft pouch, NICOSILK tech) went national in March 2026, in ~100,000 stores (~85% of pouch volume) by end of Q1. Q2 is the first full quarter of national availability — so on! PLUS consumer offtake / repeat rates are the key new datapoint. Early velocity, flavor authorizations (FDA reviewing Mint/Wintergreen/Tobacco and 12mg under its pilot; 6 more varieties submitted), and whether Helix marketing spend continues to dilute oral margins all matter.

e-vapor (NJOY): - Management remains disciplined: guidance assumes NJOY ACE does not return to market in 2026. Watch for any update on the ITC/patent-infringement resolution and re-launch timing — a positive surprise here would be an incremental catalyst, but don't expect it to move numbers this year.

Framing: oral OCI was essentially flat in Q1 as pouch mix and Helix investment offset pricing. If smoke-free stays a drag while combustibles carry the quarter, bears will argue the "transformation" is stalling; bulls will point to on! PLUS being too early to judge.

5. Capital return & balance sheet

Dividend: ~$1.8B paid in Q1; yield ~5.4% at current price. Note the annual dividend increase is typically announced in late August, so it is usually not a Q2-call event — but new management commentary on the payout is worth monitoring.
Buyback: $720M remaining on the $2B program (expires 12/31/26); ~$280M repurchased in Q1 at ~$62. With the stock now ~$75, watch whether they slow repurchases at higher prices.
Balance sheet: debt/EBITDA ~1.9x (at target); comfortable.
New this year: a ramping cigarette import/export contract-manufacturing business plus duty-drawback refunds that build progressively through 2026 — a genuine incremental profit tailwind that should be larger in Q2 than Q1.

6. Market setup & positioning

Stock: ~$75, up ~26% over the trailing year and near cycle highs; the Q1 beat drove a +6.5% one-day pop (Apr 30).
But recent history cuts both ways: MO fell ~7.8% after Q3 2025 and ~5.3% after Q4 2025 earnings — i.e., the stock has punished disappointments hard even during the overall uptrend.
Implication: expectations are elevated and the easy re-rating may be behind. A simple in-line print with a reaffirm may not be enough to extend the rally; the market likely wants (a) another quarter of volume moderation, (b) evidence on on! PLUS, and (c) a confident, "steady-hand" debut from the new CEO. Conversely, any hint of a guidance trim or a snap-back in volume declines is the downside risk given the run-up.

What I'll be watching, in priority order

Any change to FY2026 guidance ($5.56–$5.72) and the new CEO's framing of it — reaffirm vs. raise vs. cautious reset.
Cigarette industry volume decline rate — does the sequential moderation continue (~4–5%) or reverse?
on! PLUS national ramp — first full quarter of offtake, plus oral-segment margin trajectory.
Consumer health / trade-down — discount share, gas-price/refund commentary, Marlboro premium share (Cowboy Cut expansion was slated for late Q2).
Duty-drawback / export contribution — magnitude of the H2-building tailwind.
Capital return signals — buyback pace at higher prices and any pre-August dividend commentary.

Bottom line: Fundamentally the momentum favors a solid quarter — moderating volumes, pricing power, and a duty-drawback tailwind should support mid-single-digit EPS growth around $1.47–$1.51. The risk isn't the numbers; it's that a stock near highs with two recent negative earnings reactions leaves little room for error, and a first-time CEO could choose the moment to recalibrate. Watch the guide and the volume line above all.

Note: EPS scenarios are my own estimates derived from company guidance and the year-ago base, not published consensus.